Developer docs
API playgroundTry for free, no card

Search company profiles

Pharco Pharmaceuticals

Full company profile

uuid0009om1

Namestring
Pharco Pharmaceuticals
Legal namestring
Pharco Pharmaceuticals
Websiteurl
pharco.org
Company typeenum
Private
Founded yearint
1983
Descriptiontext

Pharco Pharmaceuticals is the largest pharmaceutical manufacturer in Egypt and the MENA region, operating a vertically integrated group of 11 companies with 8,000+ employees, 2.5 million+ daily pack production capacity, and exports to more than 50 countries. Founded in 1983 by Dr. Hassan Abbas Helmy and currently led by CEO Dr. Sherine Helmy, the Alexandria-headquartered group produces generics and branded generics across anti-infectives, cardiovascular, diabetes, respiratory, CNS, gastrointestinal, oncology, hormonal, and dermatology therapeutic areas, alongside specialty products such as Gratisovir (Sofosbuvir), Ravidasvir, Mirazid (antiparasitic), Pedyphar (diabetic foot), and Aloreed (psoriasis). Core manufacturing capabilities include the largest soft gelatin capsule facility in MENA (Safe Pharma, formerly RP Scherer Egypt) producing 1.5 billion+ capsules annually via rotary die technology, Egypt's first GMP-compliant Active Pharmaceutical Ingredients factory (Sofosbuvir API via non-infringing method), and dedicated beta-lactam/cephalosporin facilities under cGMP.

The business model combines volume generic manufacturing for domestic distribution through owned wholesaler Abou Kir Trading (9,000+ Egyptian pharmacies) and Romanian subsidiary Pharco Impex (4,000+ pharmacies) with government-tender-driven Hepatitis C eradication programs — most notably the Egyptian national campaign that screened 70 million people and cured 4 million+ patients, and a parallel Malaysia public-sector program via Pharmaniaga JV at US$300 per treatment course. Regulatory moats include WHO prequalification for Sofosbuvir, EU PIC/S certification, and inclusion of Ravidasvir on the WHO Essential Medicines List (2023). Revenue streams include pharmaceutical product sales (450+ brands) and the Tour n' Cure medical tourism program offering HCV treatment at under 20% of Western pricing.

Recent strategic posture is geographic and capital expansion: Ashmore Investment Saudi Arabia and SIDF acquired a minority stake in Pharco KSA to fund a 62,000 sqm manufacturing facility in Al Madinah Industrial City targeting 2027 commissioning, while the company continues to develop women's health, dermatology, and chronic disease portfolios alongside its core infectious-disease franchise.

Short descriptiontext

Pharco Pharmaceuticals is Egypt's largest pharmaceutical manufacturer and MENA region leader, producing 450+ branded generics and affordable Hepatitis C therapies (Sofosbuvir, Ravidasvir) across 11 group companies, 8,000+ employees, and 50+ export markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersAlexandria, Egypt
HQ citystring
Alexandria
HQ countrystring
Egypt
HQ regionstring
Africa
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, hepatitis C treatment, branded generics, active pharmaceutical ingredients, pharmaceutical manufacturing
Industry3 codes
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceutical Manufacturing
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pharco generates revenue through manufacturing and selling generics, branded generics, and licensed pharmaceutical products. The company produces over 450 brands covering most pharmacological groups including anti-infectives, cardiovascular, diabetes, respiratory, CNS, gastrointestinal, and oncology medications. Products are sold domestically in Egypt and exported to 50+ countries.

pharco.org
2Medical Tourism - Tour n' Cure
TypeProfessional Services
Description

International patients visit Egypt for HCV treatment through the Tour n' Cure program, combining medical treatment with tourism at significantly reduced costs compared to Western prices (under 20% of international costs).

pharco.org
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1HCV treatment affordable pricing for developing countries
ModelUnit PricingBilling cadenceOne time/ perpetual license
Notes

Ravidasvir + Sofosbuvir combination therapy sold for approximately $300 per treatment course in public sector (e.g., Malaysia), compared to $80,000+ for equivalent treatments in developed markets.

pharco.org
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Pharco Pharmaceuticals manufactures and distributes generic and branded generic pharmaceutical products across multiple therapeutic areas (anti-infectives, cardiovascular, diabetes, respiratory, CNS, gastrointestinal, oncology, hormones). It produces finished dosage forms (soft gelatin capsules, tablets, injectables) and active pharmaceutical ingredients, with WHO-prequalified and EU PIC/S-certified facilities. The company supplies over 450 brands across 11 group entities, exporting to 50+ countries and operating a Hepatitis C eradication-focused medical tourism program (Tour n' Cure).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 97-100% cure rate for Hepatitis C with ravidasvir + sofosbuvir combination therapy
+4 more records
Product overview1 text field

Pharco Pharmaceuticals is the largest pharmaceutical manufacturer in Egypt and the MENA region, operating as a diversified pharmaceutical corporation with 11 subsidiary companies. The product portfolio centers on generic and branded generic pharmaceuticals across diverse therapeutic areas including Hepatitis C antivirals (Gratisovir/Sofosbuvir and Ravidasvir), antibiotics (Cephalosporins, Penicillins), cardiovascular medications, diabetes treatments, women's health products (25 hormonal care products including contraceptives), dermatology treatments (Pedyphar for diabetic foot, Aloreed for Psoriasis), antiparasitics (Mirazid), and comprehensive ranges covering antihistamines, CNS, gastrointestinal, musculoskeletal, oncology, respiratory, and vitamins/supplements. The company also operates the Tour n' Cure medical tourism program for Hepatitis C treatment. Key brands include Gratisovir, Ravidasvir, Cefaxone, Ciprofar, Spasmo Digestin, and Mirazid, with manufacturing across soft gelatin capsules, tablets, injectables, and active pharmaceutical ingredients.

Product and service9 records
1Gratisovir (Sofosbuvir)
CategoryHepatitis C antiviral
Description

Affordable oral Hepatitis C treatment (400mg Sofosbuvir tablets), a nucleotide analog NS5B polymerase inhibitor for chronic hepatitis C infection. Used as core component of combination Hepatitis C therapy sold at approximately $300 per course in developing markets.

2Ravidasvir
CategoryHepatitis C antiviral
Description

HCV NS5A inhibitor (PPI-668) used in combination with Sofosbuvir for pangenotypic treatment of chronic Hepatitis C infection. Achieves 97-100% cure rates in clinical trials; included on the WHO Essential Medicines List (2023); licensed for low- and middle-income countries through Medicines Patent Pool.

3Mirazid
CategoryAnti-parasitic
Description

Soft gelatin capsules for the treatment of Bilharziasis (schistosomiasis), Fascioliasis and other parasitic infections.

4Pedyphar
CategoryDermatology
Description

Topical ointment for the treatment of diabetic foot ulcers.

5Aloreed
CategoryDermatology
Description

Topical ointment for the treatment of Psoriasis.

6Branded Generics Portfolio
CategoryBranded generics (multi-therapeutic)
Description

Portfolio of over 450 branded generic pharmaceuticals across multiple therapeutic areas including Antihistamines, Anti-infectives, Antipyretics, Antivirals, Blood Coagulation, Cardio Vascular System, Central Nervous System, Dermatology, Diabetes, Gastrointestinal Tract, Genito-urinary system, Gynaecology, Hormones and Systemic Corticosteroids, Hospital, Musculoskeletal, Oncology & Immunity, Respiratory, Sensory, Urology, Vitamins & Supplements. Includes named brands such as Cefaxone and Ciprofar.

7Tour n' Cure Medical Tourism Program
CategoryMedical tourism service
Description

Medical tourism initiative offering Hepatitis C patients from around the world complete treatment regimens combined with tourism opportunities in Egypt, priced at under 20% of international treatment costs with no waiting time.

8Women's Hormonal Care Product Line
CategoryHormones / women's health
Description

Set of 25 women's hormonal care products manufactured by Techno Pharma Egypt for contraception, hormonal support, and infertility treatment.

9Cephalosporin and Penicillin Antibiotics Portfolio (Cefaxone, Ciprofar)
CategoryAntibiotics (beta-lactams)
Description

Portfolio of cephalosporin and penicillin antibiotics manufactured at Pharco B International, including branded products such as Cefaxone and Ciprofar, produced in dedicated sterile and non-sterile facilities to avoid cross-contamination.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1Pharmaniaga (Malaysia)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-11-13
Description

Joint venture between Pharmaniaga and Pharco Corp of Egypt to produce ravidasvir locally in Malaysia. Collaboration with DNDi to manufacture and supply new HCV treatment regimen sold for US $300 in Malaysian public sector.

pharco.org
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-04-21
Description

License and technology transfer agreement covering affordable supply of ravidasvir (PPI-668) in certain low- and middle-income countries with high hepatitis prevalence, including Russia, Ukraine, Egypt, and Iran.

3Presidio Pharmaceuticals, Inc.
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2016-01-01
Description

Exclusive license agreement for Presidio's HCV NS5A inhibitor PPI-668 (ravidasvir) for development and commercialization to treat HCV infection in Egypt. Agreement includes opportunity to expand licensed territory to additional MENA region countries.

pharco.org
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2004-01-01
Description

Joint venture established in Saudi Arabia with Batterjee Group and EIPICO to offer wide range of pharmaceutical products to the Saudi Arabian market.

5RP Scherer Corporation
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on1993-01-01
Description

Partnership for soft gelatin capsule manufacturing technology. Establishment of R.P Scherer Egypt (now Safe Pharma), producing over 1.5 billion capsules annually using Rotary Die technology.

pharco.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharco and DNDi conducted clinical trials on ravidasvir + sofosbuvir in Malaysia and Thailand achieving 97% cure rates. DNDi licensed ravidasvir in low and middle income countries for affordable HCV treatment.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Partnership to initiate Tour n' Cure medical tourism program, encouraging patients worldwide to visit Egypt for HCV treatment with complete medical care and tourism experience.

8Italian Research and Development Laboratory
Strategic tierCoreTypeTechnology or Integration
Description

Contracted with Italian R&D laboratory to manufacture affordable HCV treatment (Sofosbuvir) to ensure continuous supply of raw materials for HCV treatments.

pharco.org
Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Saudi Arabia-based pharmaceutical manufacturer producing generics and branded generics, with strong domestic Saudi presence and Vision 2030-aligned localization strategy. Comparable to Pharco as a regional manufacturer competing for Saudi government tenders and Arabic-speaking-market share.

TypeBroad incumbent
Description

Indian global generics manufacturer with major API and finished-dose capacity, exporting broadly to Africa, MENA, and other emerging markets. Comparable to Pharco's branded-generics-plus-API model targeting similar geographies and price points.

3Julphar (Gulf Pharmaceutical Industries)
TypeDirect peer
Description

UAE-based pharmaceutical manufacturer with broad generics and branded generics portfolio across MENA. Comparable to Pharco as a regional GCC manufacturer with similar therapeutic breadth and government-tender exposure.

TypeDirect peer
Description

Egyptian pharmaceutical manufacturer focused on affordable medicines across generics, branded generics, and specialty therapies, with strong export presence across MENA and Africa. Closely comparable to Pharco in scale, therapeutic breadth, and emerging-markets focus.

TypeDirect peer
Description

Saudi Arabia-headquartered pharmaceutical manufacturer producing branded generics across cardiovascular, CNS, anti-infectives, and respiratory categories. Closely comparable to Pharco as a regional GCC manufacturer pursuing Vision 2030 localization and competing for the same Saudi government tenders.

TypeDirect peer
Description

Indian global pharmaceutical company with major presence in generics, anti-infectives, and respiratory therapies, strong across Africa and emerging markets. Comparable to Pharco as a leading emerging-markets generics manufacturer with WHO prequalification and a focus on affordable access.

TypeDirect peer
Description

One of the largest Egyptian pharmaceutical manufacturers, established in 1980, producing branded generics across multiple therapeutic areas. Direct competitor to Pharco in the Egyptian market and historically a joint-venture partner with Pharco in KSA through Batterjee Pharmaceuticals.

TypeDirect peer
Description

Jordan-headquartered generic and specialty pharmaceutical manufacturer with major MENA and US presence, producing generics across anti-infectives, cardiovascular, and CNS. Comparable to Pharco as a MENA-rooted, multi-geography generics manufacturer targeting both emerging and regulated markets.

9Sun Pharmaceutical Industries
TypeBroad incumbent
Description

India's largest pharmaceutical company and a global leader in generics, with deep presence across emerging markets including MENA and Africa. Comparable to Pharco as a generics powerhouse pursuing emerging-markets volume, though at much larger global scale.

TypeDirect peer
Description

South African pharmaceutical manufacturer with leading presence across Africa and emerging markets, focused on generics and specialty branded products. Comparable to Pharco in the role of a large emerging-markets generics champion pursuing both volume and affordability-driven models.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries9 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pharco Pharmaceuticals

Pharmaceutical Manufacturingpharco.org

Pharco Pharmaceuticals is Egypt's largest pharmaceutical manufacturer and MENA region leader, producing 450+ branded generics and affordable Hepatitis C therapies (Sofosbuvir, Ravidasvir) across 11 group companies, 8,000+ employees, and 50+ export markets.

What Pharco Pharmaceuticals does

Pharco Pharmaceuticals is the largest pharmaceutical manufacturer in Egypt and the MENA region, operating a vertically integrated group of 11 companies with 8,000+ employees, 2.5 million+ daily pack production capacity, and exports to more than 50 countries. Founded in 1983 by Dr. Hassan Abbas Helmy and currently led by CEO Dr. Sherine Helmy, the Alexandria-headquartered group produces generics and branded generics across anti-infectives, cardiovascular, diabetes, respiratory, CNS, gastrointestinal, oncology, hormonal, and dermatology therapeutic areas, alongside specialty products such as Gratisovir (Sofosbuvir), Ravidasvir, Mirazid (antiparasitic), Pedyphar (diabetic foot), and Aloreed (psoriasis). Core manufacturing capabilities include the largest soft gelatin capsule facility in MENA (Safe Pharma, formerly RP Scherer Egypt) producing 1.5 billion+ capsules annually via rotary die technology, Egypt's first GMP-compliant Active Pharmaceutical Ingredients factory (Sofosbuvir API via non-infringing method), and dedicated beta-lactam/cephalosporin facilities under cGMP.

The business model combines volume generic manufacturing for domestic distribution through owned wholesaler Abou Kir Trading (9,000+ Egyptian pharmacies) and Romanian subsidiary Pharco Impex (4,000+ pharmacies) with government-tender-driven Hepatitis C eradication programs — most notably the Egyptian national campaign that screened 70 million people and cured 4 million+ patients, and a parallel Malaysia public-sector program via Pharmaniaga JV at US$300 per treatment course. Regulatory moats include WHO prequalification for Sofosbuvir, EU PIC/S certification, and inclusion of Ravidasvir on the WHO Essential Medicines List (2023). Revenue streams include pharmaceutical product sales (450+ brands) and the Tour n' Cure medical tourism program offering HCV treatment at under 20% of Western pricing.

Recent strategic posture is geographic and capital expansion: Ashmore Investment Saudi Arabia and SIDF acquired a minority stake in Pharco KSA to fund a 62,000 sqm manufacturing facility in Al Madinah Industrial City targeting 2027 commissioning, while the company continues to develop women's health, dermatology, and chronic disease portfolios alongside its core infectious-disease franchise.

Pharco Pharmaceuticals firmographics

Firmographics
Name
Pharco Pharmaceuticals
Legal name
Pharco Pharmaceuticals
Website
https://pharco.org
Company type
Private
Founded year
1983
Operating status
Operating
Headcount range
5,001–10,000 employees
Short description
Pharco Pharmaceuticals is Egypt's largest pharmaceutical manufacturer and MENA region leader, producing 450+ branded generics and affordable Hepatitis C therapies (Sofosbuvir, Ravidasvir) across 11 group companies, 8,000+ employees, and 50+ export markets.
Ownership category
akta.pro rank

Pharco Pharmaceuticals industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Generic pharmaceuticals
  • Hepatitis C treatment
  • Branded generics
  • Active pharmaceutical ingredients
  • Pharmaceutical manufacturing

Where Pharco Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Alexandria
HQ country
Egypt
HQ region
Africa

Offices5 records

Markets served

Pharco Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Pharco generates revenue through manufacturing and selling generics, branded generics, and licensed pharmaceutical products. The company produces over 450 brands covering most pharmacological groups including anti-infectives, cardiovascular, diabetes, respiratory, CNS, gastrointestinal, and oncology medications. Products are sold domestically in Egypt and exported to 50+ countries.
  2. Medical Tourism - Tour n' Cure: International patients visit Egypt for HCV treatment through the Tour n' Cure program, combining medical treatment with tourism at significantly reduced costs compared to Western prices (under 20% of international costs).

Pricing tiers

ModelBillingPrice
Unit PricingOne time/ perpetual licenseHCV treatment affordable pricing for developing countries

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Pharco Pharmaceuticals product offering

Product offering

Core offering

Pharco Pharmaceuticals manufactures and distributes generic and branded generic pharmaceutical products across multiple therapeutic areas (anti-infectives, cardiovascular, diabetes, respiratory, CNS, gastrointestinal, oncology, hormones). It produces finished dosage forms (soft gelatin capsules, tablets, injectables) and active pharmaceutical ingredients, with WHO-prequalified and EU PIC/S-certified facilities. The company supplies over 450 brands across 11 group entities, exporting to 50+ countries and operating a Hepatitis C eradication-focused medical tourism program (Tour n' Cure).

Product overview

Pharco Pharmaceuticals is the largest pharmaceutical manufacturer in Egypt and the MENA region, operating as a diversified pharmaceutical corporation with 11 subsidiary companies. The product portfolio centers on generic and branded generic pharmaceuticals across diverse therapeutic areas including Hepatitis C antivirals (Gratisovir/Sofosbuvir and Ravidasvir), antibiotics (Cephalosporins, Penicillins), cardiovascular medications, diabetes treatments, women's health products (25 hormonal care products including contraceptives), dermatology treatments (Pedyphar for diabetic foot, Aloreed for Psoriasis), antiparasitics (Mirazid), and comprehensive ranges covering antihistamines, CNS, gastrointestinal, musculoskeletal, oncology, respiratory, and vitamins/supplements. The company also operates the Tour n' Cure medical tourism program for Hepatitis C treatment. Key brands include Gratisovir, Ravidasvir, Cefaxone, Ciprofar, Spasmo Digestin, and Mirazid, with manufacturing across soft gelatin capsules, tablets, injectables, and active pharmaceutical ingredients.

Differentiator

Problem solved

Functional benefit

Products and services

  • Gratisovir (Sofosbuvir) Affordable oral Hepatitis C treatment (400mg Sofosbuvir tablets), a nucleotide analog NS5B polymerase inhibitor for chronic hepatitis C infection. Used as core component of combination Hepatitis C therapy sold at approximately $300 per course in developing markets.
  • Ravidasvir HCV NS5A inhibitor (PPI-668) used in combination with Sofosbuvir for pangenotypic treatment of chronic Hepatitis C infection. Achieves 97-100% cure rates in clinical trials; included on the WHO Essential Medicines List (2023); licensed for low- and middle-income countries through Medicines Patent Pool.
  • Mirazid Soft gelatin capsules for the treatment of Bilharziasis (schistosomiasis), Fascioliasis and other parasitic infections.
  • Pedyphar Topical ointment for the treatment of diabetic foot ulcers.
  • Aloreed Topical ointment for the treatment of Psoriasis.
  • Branded Generics Portfolio Portfolio of over 450 branded generic pharmaceuticals across multiple therapeutic areas including Antihistamines, Anti-infectives, Antipyretics, Antivirals, Blood Coagulation, Cardio Vascular System, Central Nervous System, Dermatology, Diabetes, Gastrointestinal Tract, Genito-urinary system, Gynaecology, Hormones and Systemic Corticosteroids, Hospital, Musculoskeletal, Oncology & Immunity, Respiratory, Sensory, Urology, Vitamins & Supplements. Includes named brands such as Cefaxone and Ciprofar.
  • Tour n' Cure Medical Tourism Program Medical tourism initiative offering Hepatitis C patients from around the world complete treatment regimens combined with tourism opportunities in Egypt, priced at under 20% of international treatment costs with no waiting time.
  • Women's Hormonal Care Product Line Set of 25 women's hormonal care products manufactured by Techno Pharma Egypt for contraception, hormonal support, and infertility treatment.
  • Cephalosporin and Penicillin Antibiotics Portfolio (Cefaxone, Ciprofar) Portfolio of cephalosporin and penicillin antibiotics manufactured at Pharco B International, including branded products such as Cefaxone and Ciprofar, produced in dedicated sterile and non-sterile facilities to avoid cross-contamination.

Quantifiable outcome

  • 97-100% cure rate for Hepatitis C with ravidasvir + sofosbuvir combination therapy
  • +4 more outcomes

Companies that use Pharco Pharmaceuticals

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Pharco Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Pharco Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and major.

  • Pharmaniaga (Malaysia)coreStrategic or Co-development Partner · 13 November 2017Joint venture between Pharmaniaga and Pharco Corp of Egypt to produce ravidasvir locally in Malaysia. Collaboration with DNDi to manufacture and supply new HCV treatment regimen sold for US $300 in Malaysian public sector.
  • Medicines Patent Pool (MPP)coreStrategic or Co-development Partner · 21 April 2017License and technology transfer agreement covering affordable supply of ravidasvir (PPI-668) in certain low- and middle-income countries with high hepatitis prevalence, including Russia, Ukraine, Egypt, and Iran.
  • Presidio Pharmaceuticals, Inc.coreOEM/ Whitelabel/ Licensing Partner · 1 January 2016Exclusive license agreement for Presidio's HCV NS5A inhibitor PPI-668 (ravidasvir) for development and commercialization to treat HCV infection in Egypt. Agreement includes opportunity to expand licensed territory to additional MENA region countries.
  • Batterjee Pharmaceuticals KSAmajorChannel Partner/ Reseller/ Distributor · 1 January 2004Joint venture established in Saudi Arabia with Batterjee Group and EIPICO to offer wide range of pharmaceutical products to the Saudi Arabian market.
  • RP Scherer CorporationcoreStrategic or Co-development Partner · 1 January 1993Partnership for soft gelatin capsule manufacturing technology. Establishment of R.P Scherer Egypt (now Safe Pharma), producing over 1.5 billion capsules annually using Rotary Die technology.
  • Drugs for Neglected Diseases initiative (DNDi)coreStrategic or Co-development PartnerPharco and DNDi conducted clinical trials on ravidasvir + sofosbuvir in Malaysia and Thailand achieving 97% cure rates. DNDi licensed ravidasvir in low and middle income countries for affordable HCV treatment.
  • Prime PharmamajorChannel Partner/ Reseller/ DistributorPartnership to initiate Tour n' Cure medical tourism program, encouraging patients worldwide to visit Egypt for HCV treatment with complete medical care and tourism experience.
  • Italian Research and Development LaboratorycoreTechnology or IntegrationContracted with Italian R&D laboratory to manufacture affordable HCV treatment (Sofosbuvir) to ensure continuous supply of raw materials for HCV treatments.

Scale indicators13 records

Recent moves11 records

Expansion highlights6 records

Pharco Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): Saudi Arabia-based pharmaceutical manufacturer producing generics and branded generics, with strong domestic Saudi presence and Vision 2030-aligned localization strategy. Comparable to Pharco as a regional manufacturer competing for Saudi government tenders and Arabic-speaking-market share.
  • Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer with broad generics and branded generics portfolio across MENA. Comparable to Pharco as a regional GCC manufacturer with similar therapeutic breadth and government-tender exposure.
  • EVA Pharma: Egyptian pharmaceutical manufacturer focused on affordable medicines across generics, branded generics, and specialty therapies, with strong export presence across MENA and Africa. Closely comparable to Pharco in scale, therapeutic breadth, and emerging-markets focus.
  • Tabuk Pharmaceuticals: Saudi Arabia-headquartered pharmaceutical manufacturer producing branded generics across cardiovascular, CNS, anti-infectives, and respiratory categories. Closely comparable to Pharco as a regional GCC manufacturer pursuing Vision 2030 localization and competing for the same Saudi government tenders.
  • Cipla: Indian global pharmaceutical company with major presence in generics, anti-infectives, and respiratory therapies, strong across Africa and emerging markets. Comparable to Pharco as a leading emerging-markets generics manufacturer with WHO prequalification and a focus on affordable access.
  • EIPICO (Egyptian International Pharmaceutical Industries Company): One of the largest Egyptian pharmaceutical manufacturers, established in 1980, producing branded generics across multiple therapeutic areas. Direct competitor to Pharco in the Egyptian market and historically a joint-venture partner with Pharco in KSA through Batterjee Pharmaceuticals.
  • Hikma Pharmaceuticals: Jordan-headquartered generic and specialty pharmaceutical manufacturer with major MENA and US presence, producing generics across anti-infectives, cardiovascular, and CNS. Comparable to Pharco as a MENA-rooted, multi-geography generics manufacturer targeting both emerging and regulated markets.
  • Aspen Pharmacare: South African pharmaceutical manufacturer with leading presence across Africa and emerging markets, focused on generics and specialty branded products. Comparable to Pharco in the role of a large emerging-markets generics champion pursuing both volume and affordability-driven models.

Broad incumbents

  • Aurobindo Pharma: Indian global generics manufacturer with major API and finished-dose capacity, exporting broadly to Africa, MENA, and other emerging markets. Comparable to Pharco's branded-generics-plus-API model targeting similar geographies and price points.
  • Sun Pharmaceutical Industries: India's largest pharmaceutical company and a global leader in generics, with deep presence across emerging markets including MENA and Africa. Comparable to Pharco as a generics powerhouse pursuing emerging-markets volume, though at much larger global scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Pharco Pharmaceuticals social profiles

Digital presence

Pharco Pharmaceuticals compliance and trust

Trust signal

Compliance3 records

Pharco Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pharco Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles4 records

Pharco Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries9 records

Pharco Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pharco Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharco Pharmaceuticals

What does Pharco Pharmaceuticals do?

Pharco Pharmaceuticals manufactures and distributes generic and branded generic pharmaceutical products across multiple therapeutic areas (anti-infectives, cardiovascular, diabetes, respiratory, CNS, gastrointestinal, oncology, hormones). It produces finished dosage forms (soft gelatin capsules, tablets, injectables) and active pharmaceutical ingredients, with WHO-prequalified and EU PIC/S-certified facilities. The company supplies over 450 brands across 11 group entities, exporting to 50+ countries and operating a Hepatitis C eradication-focused medical tourism program (Tour n' Cure).

Is Pharco Pharmaceuticals a public or private company?

Pharco Pharmaceuticals is a private company. It is classified as family owned and is currently operating.

When was Pharco Pharmaceuticals founded?

Pharco Pharmaceuticals was founded in 1983. It employs 5,001 to 10,000 people.

Where is Pharco Pharmaceuticals based?

Pharco Pharmaceuticals is headquartered in Alexandria, Egypt, in the Africa region.

How does Pharco Pharmaceuticals make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are medical Tourism - Tour n' Cure.

Who are Pharco Pharmaceuticals's main competitors?

Direct peers on record are SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation), Julphar (Gulf Pharmaceutical Industries), EVA Pharma, Tabuk Pharmaceuticals, Cipla, EIPICO (Egyptian International Pharmaceutical Industries Company), Hikma Pharmaceuticals and Aspen Pharmacare. Broad incumbents are Aurobindo Pharma and Sun Pharmaceutical Industries.

Does Pharco Pharmaceuticals have an API?

No public API is recorded for Pharco Pharmaceuticals.

What industry is Pharco Pharmaceuticals in?

Pharco Pharmaceuticals's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EnterpriseamPharco doubles down on local capex and Gulf expansion amid pricing squeezePharco is investing in local capacity and Gulf expansion to offset a pricing squeeze where production costs outpace price adjustments. The company targets EGP 18 billion in sales by year-end and is building a Saudi plant in Medina, with production expected in 2028. Egypt remains its export hub serving 50 global markets.ZawyaEgypt: Pharco Pharmaceuticals plans $28mln investments to expand production, exportsPharco Pharmaceuticals plans to invest about EGP 1.5bn next year to expand production and exports, up from EGP 1.15bn in 2025. The company is building a 62,000 sqm plant in Saudi Arabia with $150m investment, targeting Gulf markets. It also plans an African manufacturing network amid TRIPS-related regulatory changes.ZawyaPharco Pharmaceuticals launches “Vision for All” initiativePharco Pharmaceuticals launched its 'Vision for All' initiative to advance ophthalmic healthcare in Egypt and the region, focusing on glaucoma early detection and medical convoys. The initiative coincides with a new ophthalmic eye drops production line in Alexandria, with total investments exceeding EGP 500 million and annual capacity of 20 million packs.ZawyaRavidasvir receives approval in Thailand for the treatment of Hepatitis CThe Thai FDA approved Ravidasvir for hepatitis C treatment, following registration in Malaysia and Egypt. The drug, taken once daily for 12 weeks with sofosbuvir, showed high efficacy and safety, including in HIV co-infected patients. DNDi and partners plan to expand registration into Latin American markets.ZawyaEgypt’s Pharco opens $5.8mln ophthalmic products line in Alexandria facilityPharco Pharmaceuticals inaugurated a new ophthalmic drops production line at its Alexandria facility, part of a 500 million Egyptian pounds ($9.6 million) expansion programme. The line is part of the wider expansion, which includes other investments.TradingViewZAWYA-PRESSR: Ashmore Industrial Initiative makes first investment with Pharco Pharmaceuticals in 62,000-sqm manufacturing facilityAshmore Investment Saudi Arabia has made its first investment under its Industrial Initiative by acquiring a minority stake through a primary capital increase in Pharco KSA, the Saudi subsidiary of Pharco Pharmaceuticals, with the signing taking place at the PIF Private Sector Forum. The investment will fund construction of a 62,000 square metre pharmaceutical manufacturing facility in Al Madinah Industrial City, designed to produce solid oral dosage forms and injectables for cardiovascular, diabetes and respiratory therapies, targeting commencement of local operations in 2027. The transaction represents a strategic partnership supporting Saudi Arabia's Vision 2030 objectives for pharmaceutical localization and industrial diversification, with SIDF Investment Company serving as anchor investor.PR NewswireThe Medicines Patent Pool and Pharco Pharmaceuticals Sign Licence for Promising Hepatitis C Drug Candidate RavidasvirThe Medicines Patent Pool (MPP) and Egyptian company Pharco Pharmaceuticals signed a licence and technology transfer agreement on April 21, 2017 in Amsterdam for ravidasvir (RAV), an investigational hepatitis C direct-acting antiviral. The agreement enables competitive supply of RAV in low- and middle-income countries including high-prevalence nations Russia, Ukraine, Egypt, and Iran. Ravidasvir demonstrated cure rates of up to 100% in Phase III trials in Egypt and, combined with existing MPP and DNDi licences, could benefit countries where 85.3% of people living with hepatitis C in LMICs reside.